Mosaic ImmunoEngineering is a nanotechnology-based immunotherapy company developing therapeutics and vaccines to positively impact the lives of patients and their families.

Free
Message: Thinking/wondering

Thinking/wondering

posted on Oct 27, 2009 10:52AM

<hundreds of companies have been awaiting the outcome of US’336 and are now reengaging in licensing discussions in light of the escalating royalty rate structure of the MMP Portfolio™ Licensing Program.>

We know for a fact that we have been negotiating with many of these companies for years. If the above is a fair description of events, then I'm wondering how they allocate their time? How do they determine which potential licensee to spend their time on? This may be part of the problem if they don't have some sort of priority list/pecking order established. And I'm not sure how you get one that is reflective of which targets are most likely to accept w/o drawn out negotiations.

Anyone out there have any thoughts on the process to handle the above situation?

Opty

Share
New Message
Please login to post a reply